20 Jul 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO Giles Bourne gives an update on the commissioning of the BLG 500 at Silverwater, strategic alliances and product roadmap.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.
08 Jul 2020 - Renergen Limited (ASX:RLT) Managing Director and CEO Stefano Marani talks about the company's high concentration of helium from Phase 1 drill results at its Virginia Gas Field in the Karoo Basin, South Africa.
7 July 2020 - Renergen (ASX:RLT) Managing Director, Stefano Marani talks about its high concentration of helium from Phase 1 drill results at its Virginia Gas Field in the Karoo Basin, South Africa.
24 Jun 2020 - Acorn Capital, portfolio manager Rick Squire talks about the energy and resource sectors, some of the funds best ideas and outlook for commodities and energy prices as the world emerges from OCIVD-19 lockdown.
24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.
23 June 2020 - Renergen Limited (ASX:RLT) Managing Director Stefano Marani talks about the significance of the company's marketing and distribution agreement with Total South Africa for LNG from Phase 1 of its project.
22 Jun 2020 - An interview with Andrew Schwartz, Group Managing Director and Chief Investment Officer of Qualitas.
16 June 2020 - Social Tree Global co-founders, Max Hannah and James Saward-Anderson share their top 5 hacks for harnessing the power of social media in financial services.
16 Jun 2020 - Zelira Therapeutics Limited (ASX:ZLD) Managing Director Ex USA, Dr Richard Hopkins talks about the company's pipeline of products in clinical development targeting insomnia, chronic pain and autism, its model for rapid commercialisation, its go-to-market strategy and first revenues from US licensing partners.
